Albert Labs Inc announced it is raising up to C$4 million via a brokered private placement ahead of its anticipated RTO on the Canadian Securities Exchange.
The financing consists of up to 16 million subscription receipts priced at C$0.25 per receipt for aggregate proceeds of up to $4 million, with a 25% over-allotment option that could potentially add another $1 million to the total.
The psychedelic medicine company is in the midst of a merger transaction with ME Resource Corp that is expected to close shortly.
READ: Albert Labs inks definitive reverse takeover agreement with ME Resource Corp, moves closer to CSE listing
In a statement, Vancouver-based Albert Labs said that once the receipt conditions are satisfied, each subscription receipt will automatically convert into one share of the public company.
Research Capital Corporation is leading a syndicate of agents including Beacon Securities Limited in the transaction. Once the deal is closed, the agents will receive a 7% commission based on the gross proceeds from the subscription receipts and a number of broker warrants equal to 7% of the subscription receipts sold.
Each broker warrant will be exercisable to buy one share of the company at $0.25 for a two-year period.
Albert Labs uses real-world evidence studies to enhance patient care by accelerating access to psychedelic therapy in a hospital setting for niche indications with urgent and high unmet needs.
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas